CY1113080T1 - ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ, ΓΛΥΚΟΚΟΡΤΙΚΟΕΙΔΩΝ ΚΑΙ β2-ΑΓΩΝΙΣΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ - Google Patents

ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ, ΓΛΥΚΟΚΟΡΤΙΚΟΕΙΔΩΝ ΚΑΙ β2-ΑΓΩΝΙΣΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ

Info

Publication number
CY1113080T1
CY1113080T1 CY20121100780T CY121100780T CY1113080T1 CY 1113080 T1 CY1113080 T1 CY 1113080T1 CY 20121100780 T CY20121100780 T CY 20121100780T CY 121100780 T CY121100780 T CY 121100780T CY 1113080 T1 CY1113080 T1 CY 1113080T1
Authority
CY
Cyprus
Prior art keywords
anticholinergics
glucocorticoids
treatment
agonists
inflammatory diseases
Prior art date
Application number
CY20121100780T
Other languages
English (en)
Inventor
Joachim Dr Maus
Horst Kastrup
Peter Jürgen Cnota
Artur Bauhofer
Istvan Szelenyi
Original Assignee
Meda Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37872413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113080(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Pharma Gmbh & Co. Kg filed Critical Meda Pharma Gmbh & Co. Kg
Publication of CY1113080T1 publication Critical patent/CY1113080T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση σχετίζεται με καινοφανείς συνδυασμούς που βασίζονται σε αντιχολινεργικά, αγωνιστές β2-αδρενοϋποδοχέα, και γλυκοκορτικοειδή, διεργασία για την παραγωγή τους και τη χρήση τους για την αντιμετώπιση φλεγμονωδών νόσων, κατά προτίμηση αναπνευστικών νόσων όπως βρογχικό άσθμα και χρόνιες αποφρακτικές πνευμονικές νόσοι ("CΟΡD") ή ρευματικές ή αυτοάνοσες νόσοι.
CY20121100780T 2005-12-21 2012-08-30 ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ, ΓΛΥΚΟΚΟΡΤΙΚΟΕΙΔΩΝ ΚΑΙ β2-ΑΓΩΝΙΣΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ CY1113080T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75205805P 2005-12-21 2005-12-21
EP09006788A EP2098248B1 (en) 2005-12-21 2006-12-01 Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
CY1113080T1 true CY1113080T1 (el) 2016-04-13

Family

ID=37872413

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091101104T CY1110519T1 (el) 2005-12-21 2009-10-23 Συνδυασμος r,r-γλυκοπυρρολικου, ρολιπραμης και βουδεσονιδης για την αντιμετωπιση φλεγμονωδων νοσων
CY20121100780T CY1113080T1 (el) 2005-12-21 2012-08-30 ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ, ΓΛΥΚΟΚΟΡΤΙΚΟΕΙΔΩΝ ΚΑΙ β2-ΑΓΩΝΙΣΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20091101104T CY1110519T1 (el) 2005-12-21 2009-10-23 Συνδυασμος r,r-γλυκοπυρρολικου, ρολιπραμης και βουδεσονιδης για την αντιμετωπιση φλεγμονωδων νοσων

Country Status (20)

Country Link
US (2) US8048910B2 (el)
EP (2) EP1971369B1 (el)
JP (1) JP5107933B2 (el)
CN (1) CN101321539B (el)
AT (1) ATE439834T1 (el)
AU (1) AU2006329042B2 (el)
CA (2) CA2824075C (el)
CY (2) CY1110519T1 (el)
DE (1) DE602006008665D1 (el)
DK (2) DK1971369T3 (el)
ES (2) ES2389231T3 (el)
HK (1) HK1123497A1 (el)
HR (2) HRP20090498T1 (el)
NO (1) NO20083090L (el)
NZ (2) NZ568349A (el)
PL (2) PL2098248T3 (el)
PT (2) PT1971369E (el)
RU (1) RU2465915C2 (el)
SI (2) SI2098248T1 (el)
WO (1) WO2007071313A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1713473T3 (pl) * 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
PT2068889T (pt) * 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
CN101474191B (zh) * 2009-01-21 2011-03-23 李虎山 一种治疗哮喘和慢性阻塞性肺病的药物组合物
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111926T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
EP2515855B3 (en) * 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
BR112013008974A2 (pt) * 2010-10-12 2023-12-19 Cipla Ltd Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
CN102247380A (zh) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 一种以布地奈德与茚达特罗为活性成分的复方制剂
NZ710726A (en) * 2013-01-28 2020-08-28 Incozen Therapeutics Pvt Ltd Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
AU2014249456B2 (en) 2013-03-13 2018-08-09 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US10058661B2 (en) 2014-12-04 2018-08-28 Norton (Waterford) Limited Inhalation monitoring system and method
JP6528314B2 (ja) * 2015-03-20 2019-06-12 国立大学法人山口大学 Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
CN111228257A (zh) * 2020-03-03 2020-06-05 中国人民解放军南部战区总医院 咯利普兰在制备治疗脓毒症心功能障碍的药物中的应用
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0706513B1 (de) * 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
AU745331B2 (en) * 1996-11-11 2002-03-21 Meda Pharma Gmbh & Co. Kg Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) * 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
EP1102579B1 (de) 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
US6745467B1 (en) * 1999-02-10 2004-06-08 Canon Kabushiki Kaisha Method of producing a liquid discharge head
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
GB9918760D0 (en) * 1999-08-09 1999-10-13 Darwin Discovery Ltd Topical treatment
US20040028958A1 (en) 2002-06-18 2004-02-12 Total Innovative Manufacturing Llc Recyclable fire-resistant moldable batt and panels formed therefrom
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
ATE375142T1 (de) 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
JP2005508861A (ja) 2001-05-25 2005-04-07 ファイザー・インク 閉塞性気管疾患の治療のためのｐｄｅ４阻害剤及び抗コリン性剤の組み合わせ物
MXPA03010791A (es) 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
EP2319584A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium
WO2004023984A2 (en) * 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
EP1610788A1 (en) 2003-03-28 2006-01-04 ALTANA Pharma AG Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
ATE384529T1 (de) * 2003-03-28 2008-02-15 Nycomed Gmbh Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
US20060155491A1 (en) 2003-07-11 2006-07-13 Peter Bode Frequency determination
KR20070007075A (ko) * 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
PL1713473T3 (pl) * 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
EP1718336B1 (en) * 2004-02-06 2008-06-25 MEDA Pharma GmbH & Co. KG Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
DE102004056579A1 (de) * 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid
JP2008534611A (ja) * 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases

Also Published As

Publication number Publication date
EP2098248B1 (en) 2012-06-06
US8048910B2 (en) 2011-11-01
US20120076739A1 (en) 2012-03-29
HRP20090498T1 (en) 2009-10-31
NO20083090L (no) 2008-09-11
EP2098248A1 (en) 2009-09-09
AU2006329042A1 (en) 2007-06-28
WO2007071313A3 (en) 2007-10-11
ES2389231T3 (es) 2012-10-24
US20070196285A1 (en) 2007-08-23
ATE439834T1 (de) 2009-09-15
DE602006008665D1 (de) 2009-10-01
PL1971369T3 (pl) 2010-01-29
CA2632780C (en) 2013-11-12
HRP20120708T1 (hr) 2012-10-31
EP1971369A2 (en) 2008-09-24
SI1971369T1 (sl) 2009-12-31
CN101321539B (zh) 2010-09-29
DK2098248T3 (da) 2012-09-17
PT2098248E (pt) 2012-08-27
JP5107933B2 (ja) 2012-12-26
NZ568349A (en) 2011-05-27
NZ591969A (en) 2012-05-25
US8518918B2 (en) 2013-08-27
EP1971369B1 (en) 2009-08-19
HK1123497A1 (en) 2009-06-19
CN101321539A (zh) 2008-12-10
SI2098248T1 (sl) 2012-09-28
WO2007071313A2 (en) 2007-06-28
PT1971369E (pt) 2009-10-20
DK1971369T3 (da) 2009-11-16
CY1110519T1 (el) 2015-04-29
AU2006329042B2 (en) 2012-02-02
CA2632780A1 (en) 2007-06-28
JP2009520711A (ja) 2009-05-28
RU2465915C2 (ru) 2012-11-10
PL2098248T3 (pl) 2012-11-30
CA2824075A1 (en) 2007-06-28
ES2330047T3 (es) 2009-12-03
CA2824075C (en) 2015-04-28
RU2008129600A (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
CY1113080T1 (el) ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ, ΓΛΥΚΟΚΟΡΤΙΚΟΕΙΔΩΝ ΚΑΙ β2-ΑΓΩΝΙΣΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ
DK2018380T3 (da) CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2007114848A3 (en) Chemical compounds
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
EA200870282A1 (ru) Производные амина
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
WO2008155069A3 (de) Substituierte oxazolidinone und ihre verwendung
EA201190108A1 (ru) Фармацевтическая композиция для ингаляции
EA200800667A1 (ru) Аптамеры, связывающие тромбин с высокой аффинностью
WO2007102883A3 (en) Chemical compounds
WO2007062318A3 (en) Chemical compounds
WO2010080757A3 (en) Combinations with an alpha-4beta-2 nicotinic agonist
EP2120935A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2006086609A3 (en) Inhibitors of tryptase
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
EP2125728A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
MX2021015553A (es) Inhibidores de arginasa novedosos.
SE0701694L (sv) Nya bronkdilaterande a,b-omättade amider
ATE553088T1 (de) Substituierte chinolone ii
WO2010025436A3 (en) Nitrogen and sulfur-containing heterocycle derivatives
DE502006008280D1 (de) Imino-oxazolidine und ihre verwendung als antikoagulantien